07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Chugai, Taisho Pharmaceutical Holdings, Roche sales and marketing update

Chugai and Taisho launched a monthly oral formulation of Boniva ibandronate in Japan to treat osteoporosis. The National Health Insurance (NHI) price of a 100 mg tablet, the recommended monthly dose, is Y2,790 ($25.11). Chugai...
08:00 , Mar 7, 2016 |  BioCentury  |  Product Development

Getting hip in osteoporosis

Investors were quick to conclude that Amgen Inc. and UCB Group's romosozumab may be at a disadvantage in the osteoporosis market after the partners reported a miss on non-vertebral fracture rates, and an apparently lower...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Boniva ibandronate regulatory update

Chugai and Taisho said Japan approved a monthly oral formulation of Boniva ibandronate to treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho in 2006 to co-develop and...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Boniva ibandronate: Phase III data

The double-blind, Japanese Phase III MOVEST trial in about 400 osteoporosis patients ages >55 showed that 100 mg oral Boniva was non-inferior to IV Bonviva ibandronate on the primary endpoint of the change from baseline...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Boniva ibandronate regulatory update

Chugai submitted an NDA in Japan for a monthly oral formulation of Boniva ibandronate to treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho in 2006 to co-develop...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Actavis, Apotex, Dr. Reddy's, Mylan, Orchid Chemicals & Pharmaceuticals, Roche musculoskeletal news

The U.S. Court of Appeals for the Federal Circuit reaffirmed a lower court's decision and found invalid claims related to once-monthly oral administration of Roche's Boniva ibandronate to treat osteoporosis. In Hoffmann-La Roche Inc. et...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Chugai, Taisho Pharmaceutical Holdings sales and marketing update

Chugai and Taisho launched monthly IV Bonviva ibandronate in Japan to treat osteoporosis. The product has a Japanese National Health Insurance (NHI) list price of ¥4,918 ($49.92) per 1 mg syringe, the recommended monthly dose....
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Boniva Ibandronate regulatory update

Chugai and Taisho said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for monthly IV Bonviva ibandronate to treat osteoporosis. Chugai partnered with Taisho in 2006 to co-develop and co-market the bisphosphonate...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Boniva IV ibandronate regulatory update

Chugai submitted an NDA to the Japanese Ministry of Health, Labor and Welfare (MHLW) for monthly IV ibandronate for osteoporosis. Chugai partnered with Taisho in 2006 to co-develop and co-market the bisphosphonate that inhibits osteoclast-mediated...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity....